Disease Landscape and Forecast Insights

Triptans have long been the mainstay of acute treatment of migraine, but in Q1 2020, three novel oral nontriptans—Eli Lilly’s Reyvow, AbbVie / Allergan’s Ubrelvy, and Biohaven’s Nurtec ODT…

According to Clarivate epidemiology, more than 30 million people in the United States suffer from migraines. Despite being underused, migraine prophylaxis is a core treatment approach to reduce the…

Prophylactic therapy for migraine is prescribed to reduce migraine frequency, severity, and duration of attacks and to increase responsiveness of attacks to acute treatment. Generic oral AEDs (e.g…

The market for prescription migraine therapies comprises an array of acute and prophylactic treatments and fosters a large and dynamic pipeline. In the acute space, we anticipate the launch of…

Migraine presents a major public health burden in China, leading to impaired quality of life, widespread health loss, and loss of productivity for a sizeable population. Owing to migraine’s…

According to DRG epidemiology, over 30 million people in the EU5 suffer migraines and over 10% of migraineurs suffer chronic migraine. Migraine prophylaxis is a core treatment approach for high-…

A range of oral and nonoral triptans (e.g., sumatriptan) are available for the acute treatment of migraine and are entrenched in medical practice. However, triptans have noted clinical shortcomings…

2020 will be a turning point for the U.S. acute migraine market. Three novel therapies—Allergan’s Ubrelvy, Eli Lilly’s Reyvow, and Biohaven’s Nurtec ODT—entered the market in rapid…

According to DRG epidemiology, more than 35 million people in the United States suffer from migraines. Despite being underutilized, migraine prophylaxis is a core treatment approach to reduce…

The market for prescription migraine therapies comprises an array of prescription acute and prophylactic treatments and fosters a large and dynamic pipeline. In the acute space, we anticipate the…

The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a fourth in 2020. Amgen/Novartis’s Aimovig (…

Recent European approval of three anti-CGRP-targeted MAbs—Aimovig (Novartis), Ajovy (Teva) and Emgality (Eli Lilly)—together with the expected market penetration of the fourth anti-CGRP-…